CStone, Kimia Pharma Enter Clinical Collaboration For Solid Tumour Program; Stock Up

CStone Pharmaceuticals (2616.HK) announced a clinical collaboration agreement with Kimia Therapeutics to advance development of an asset targeting the DNA damage response (DDR) pathway, which is described as critical for solid tumour cell survival. The article excerpt says CStone will lead but cuts off before specifying what it will lead; it provides no financial terms or clinical results.